Abstracts

References

• Bloomfield CD, Lawrence C, Arthur DC, Berg DT, Schiffer CA, Mayer RJ. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994; 84(suppl 1)111a, abstract
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davis RB, Schiffer CA, et al. Intensive post-remission chemotherapy in adults with acute myeloid leukemia. N Engl J Med 1994; 331: 896–903
   PubMed Web of Science ®Google Scholar
• Robertson LE, et al. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-dexoyadenosine and 9–β-D-ara-binosyl-2-fluoroadenine. Blood 1993; 81: 143–150
   PubMed Web of Science ®Google Scholar
• Zinzasi PL, et al. Apoptosis induction with three nucleoside analogs on freshly isolated B-chronic lymphocytic leukemia cells. Am J Hematol 1994; 47: 301–306
   PubMed Web of Science ®Google Scholar
• Plunkett W, et al. Metabolism and action of fludarabine phosphate. Semin Oncol 1990; 17(suppl 8)3–17
   PubMed Web of Science ®Google Scholar
• Keating MJ, et al. Clinical experience with fludarabine in leukemia. Drugs 1994; 47(suppl 6)39–49
   PubMedGoogle Scholar
• Saven A, et al. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 570–574
   PubMed Web of Science ®Google Scholar
• Hiddeman W, Pott-Hoeck C. Fludarabine in the management of malignant lymphomas. Drugs 1994; 47(suppl 6)50–56
   PubMedGoogle Scholar
• Hoffman MA. Cladribine (2-CdA) in non-Hodgkins lymphoma: recent trials and future directions. Semin Oncol, In press
   Google Scholar
• Dimopoulos MA, et al. Fludarabine therapy in Waldenstroms macroglobulinemia. Am J Med 1994; 95: 49–52
   Web of Science ®Google Scholar
• Dimopoulos MA, et al. Primary therapy of Waldenstroms macroglobulinemia with 2–chlorodeoxyadenosine. J Clin Oncol 1994; 12: 2694–2698
   PubMed Web of Science ®Google Scholar
• Dellanoy A, et al. 2-Chlorodeoxyadenosine and multiple myeloma. EurJ Hematol 1994; 53: 181–182
   PubMed Web of Science ®Google Scholar
• Piro I, et al. The Scripps Clinic experience with 2-chlorodeoxy-adenosine in the treatment of hairy cell leukemia. Leuk Lymphoma 1994; 14(suppl 1)121–125
   PubMed Web of Science ®Google Scholar
• Lauria F, et al. Retreatment with 2-CdA of progressed HCL patients. LeukLymphoma 1994; 14(suppl 1)143–145
   PubMedGoogle Scholar
• Juliusson G, et al. Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1992; 327: 1056–1061
   PubMed Web of Science ®Google Scholar
• Dellanoy, et al. 2-Chlorodeoxyadenosine for patients with B-cell chronic lymphocytic leukemia resistant to fludarabine. N Engl J Med 1993; 328: 812
   Google Scholar
• Saven, et al. 2-Chlorodeoxyadenosine for patient with B-cell CLL resistant to fludarabine. N Engl J Med 1993; 328: 812–813
   PubMed Web of Science ®Google Scholar
• Dellanoy, et al. 2-Chlorodeoxyadenosine therapy in advanced chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1994; 36: 311–315
   PubMedGoogle Scholar
• Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A. Immunotherapy with interleukin-2 with or without lymphokine activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transplantation 1995; 16, in press
   PubMed Web of Science ®Google Scholar
• Fefer A, Benyunes MC, Massumoto C, Higuchi C, York A, Buckner CD, Thompson JA. Interleukin-2 therapy after autologous bone marrow transplantation for hematological malignancies. Semin Oncol 1993; 20(suppl 9)41–45
   PubMedGoogle Scholar
• Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A. Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 1991; 77: 2561–2568
   PubMed Web of Science ®Google Scholar
• Neubauer MA, Benyunes MC, Thompson JA, Bensinger WI, Lindgren CG, Buckner CD, Fefer A. Lymphokine-activated killer (LAK) precursor cell activity is present in infused peripheral blood stem cells and in the blood after autologous peripheral blood stem cell transplantation. Bone Marrow Transplantation 1994; 13: 311–316
   PubMed Web of Science ®Google Scholar
• Alexanian R, Dimopoulos MA, Delasalle K, et al. Primary dexa-methasone treatment of multiple myeloma. Blood 1992; 80: 887–890
   PubMed Web of Science ®Google Scholar
• Anderson KC, Andersen J, Soiffer R, et al. A monoclonal antibodypurged bone marrow transplantation therapy for multiple myeloma. Blood 1993; 82: 2568–2576
   PubMed Web of Science ®Google Scholar
• Attai M, Harousseau JL, Stoppa AM, et al. Allogeneic bone marrow transplantation in multiple myeloma: a prospective randomized study of the “Intergroupe Francais du Myelome” (IFM). Blood 1993; 82: 198a
   Google Scholar
• Attai J, Huguet M, Schiaifer D, et al. Intensive combined therapy for previously treated aggressive myeloma. Blood 1992; 79: 1130–1136
   PubMed Web of Science ®Google Scholar
• Barlogie B. Plasma cell myeloma. Hematology, E Beutler, MA Lichtman, BS Coller, et al. McGraw-Hill, New York 1994
   Google Scholar
• Barlogie B, Alexanian R, Dicke K, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987; 70: 869–872
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anderson K, Berenson J, et al. Transplants for multiple myeloma. Bone Marrow Transplantation 1994, in press
   Web of Science ®Google Scholar
• Barlogie B, Hall R, Zander R, et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298–1301
   PubMed Web of Science ®Google Scholar
• Barlogie B, Jagannath S, Vesole D, et al. Total therapy (TT) for 202 newly diagnosed patients (PTS) with multiple myeloma (MM). Blood Abstract 1994; 1531
   Google Scholar
• Bensinger WI, Appelbaum F, Clift R, et al. Phase I study of bulsufan and cyclophosphamide in preparation for allogeneic marrow transplant for patients with multiple myeloma. J Clin Oncol 1992; 10: 1492–1497
   PubMed Web of Science ®Google Scholar
• Cunningham D, Paz-Ares L, Milan S, et al. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759
   PubMed Web of Science ®Google Scholar
• Cunningham D, Powles R, Malpas JS, et al. A randomized trial of maintenance therapy with intron-A following high dose melphalan and autologous bone marrow transplant in myeloma. Proc Am Soc Clin Oncol 1993; 12: 364
   Google Scholar
• Dunbar CE, Neinhuis A. Multiple myeloma: new approaches to therapy. JAMA 1993; 269: 2412–2416
   PubMed Web of Science ®Google Scholar
• Fermand JP, Chevert S, Ravaud P, et al. High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood 1993; 82: 2005–2009
   PubMed Web of Science ®Google Scholar
• Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. N Engl J Med 1991; 325: 1267–1273
   PubMed Web of Science ®Google Scholar
• Harousseau JL, Milpied N, Laporte JP, et al. Double-intensive therapy in high risk multiple myeloma. Blood 1992; 79: 2827–2833
   PubMed Web of Science ®Google Scholar
• Jagannath S, Vesole DH, Glenn L, et al. Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 1992; 80: 1666–1672
   PubMed Web of Science ®Google Scholar
• Salmon S, Crowley J, Grogan T, Finley P, Pugh R, Barlogie B. Combination chemotherapy, glucocorticoids and interferon alpha in the treatment of multiple myeloma. A Southwest Oncology Group study. J Clin Oncol 1994; 12(11)2405–2414
   PubMed Web of Science ®Google Scholar
• Vesole DH, Jagannath S, Tricot G, et al. 400 Autotransplants (AT) for multiple myeloma (MM). Blood Abstract 1994; 2126
   Google Scholar
• McCloskey DE, Davidson NE. Paclitaxel-induced programmed cell death in human breast cancer cells. Proc Am Assoc Cancer Res 1995; 36: 416, Abstract
   Google Scholar
• Rowinsky EK, Donehower RC, Jones RJ, et al. Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 1988; 48: 4093–4100, Abstract
   PubMed Web of Science ®Google Scholar
• Kohn EC, Sarosy G, Bicher A, et al. Dose-intense taxol: high response rate in patients with platinum-resistant ovarian cancer. J Natl Cancer Inst 1994; 86: 186–24, Abstract
   Google Scholar
• Alberts DS, Krutzsch M, Wymer J, et al. Experimental rationale for 24 vs. 3 hour paclitaxel infusion schedules in the treatment of advanced ovarian cancer. Proc Am Assoc Cancer Res 1995; 36: 363, Abstract
   Google Scholar
• Wilson WH, Berg SL, Bryant G, et al. Paclitaxel in doxorubicin-re-fractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J ClinOncol 1994; 12: 1621–1629, Abstract
   PubMed Web of Science ®Google Scholar
• Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180–190, Abstract
   PubMed Web of Science ®Google Scholar
• Peters WP, Eder JP, Henner WD, et al. High-dose combination al-kylating agents with autologous bone marrow support: a phase I trial. J Clin Oncol 1986; 4: 646–654, Abstract
   PubMed Web of Science ®Google Scholar
• Goldberg HL, Vannice SB. Pneumonitis related to treatment with paclitaxel. J Clin Oncol 1995; 13: 534–535, Abstract
   PubMed Web of Science ®Google Scholar
• Fruchtman SM, Scigliano E, Ross V, et al. Bone marrow transplantation at the Mount Sinai Hospital. Mount Sinai J Med 1994; 61: 3
   PubMed Web of Science ®Google Scholar
• Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord: a clinically useful source of transplantable hematopoietic stem/progenitor cells. PNAS 1989; 86: 3828
   PubMed Web of Science ®Google Scholar
• Wagner JE, Broxmeyer HE, Byrd RL, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraft-ment. Blood 1992; 79: 1874
   PubMed Web of Science ®Google Scholar
• Wilson WH, Berg S, Bryant G, et al. Paclitaxel in doxorubicin-re-fractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion. J Clin Oncol 1994; 12: 1621–1629
   PubMed Web of Science ®Google Scholar
• McGuire WP, Rowinsky EK, Rosenshein NB, et al. Taxol: a unique anti-neoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 1989; 111: 273–279
   PubMed Web of Science ®Google Scholar
• Thornton D, Singh K, Putz B, et al. A phase II trial of Taxol in squamous cell carcinoma of the head and neck. Proc Am Soc Clin Oncol 1994; 13: 288
   Google Scholar
• Hutter H, Motzer R, Schwartz L, et al. Phase II trial of Taxol in cisplatin-resistant germ cell tumor (GCT) patients (pts). Proc Am Soc Clin Oncol 1994; 13: A712
   Google Scholar
• Reichman BS, Seidman AD, Crown JP, et al. Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 1993; 11: 1943–1951
   PubMed Web of Science ®Google Scholar
• Schiller JH, Storer B, Tutsch K, et al. Phase I trial of 3-hour infusion of paclitaxel with or without granolocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol 1994; 12: 241–248
   PubMed Web of Science ®Google Scholar
• Seidman AD, Hochhauser D, Yao T-J, et al. 96-hour paclitaxel after prior short taxane infusion: phase II pharmacokinetic (PK) and pharmacodynamic (PD) study in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 1995; 14: A151
   Google Scholar
• Wilson HW, Chabner BA, Bryant G, et al. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 1995; 13: 381–386
   PubMed Web of Science ®Google Scholar
• Younes A, Sarris A, Melnyk A, et al. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma. J Clin Onol 1995; 13: 583–587
   PubMed Web of Science ®Google Scholar
• Schally A. Oncological applications of somatostatin analogues. Cancer Res 1988; 48: 6877–6885
   Google Scholar
• Weckbecker G, Raulf F, Stolz B, Bruns C. Somatostatin analogues for diagnosis and treatment of cancer. Pharmac Ther 1993; 60: 245–264
   PubMed Web of Science ®Google Scholar
• Buscail L, Delesque N, Esteve J, et al. Stimulation of tyrosine phos-phatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994; 91: 2315–2319
   PubMed Web of Science ®Google Scholar
• van Eijck CH, Krenning EP, Bootsma A, Lindemans J, Jeekel J, Reubi JC, Lamberts SW. Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 1994; 343: 640–643
   PubMed Web of Science ®Google Scholar
• Pollak MN, Polychronakos C, Guyda H. Somatostatin analogue SMS 201–995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticancer Res 1989; 9: 889–892
   PubMed Web of Science ®Google Scholar
• Huynh HT, Pollak MN. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 1994; 203: 253–259
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Tolcsvai L, Pollak M, Bruns C. Enhancement of the antineoplastic activities of tamoxifen and ovariectomy in the DMBA-induced mammary carcinoma model by the somatostatin analogue octreotide. Cancer Res 1994; 54: 6334–6337
   PubMed Web of Science ®Google Scholar
• Alberts D, Liu P, Hannigan E, et al. Phase III study of intraperitoneal cisplatin/intravenous cyclophosphamide versus IV cisplatin/IV cyclophosphamide in patients with optimal disease stage III ovarian cancer: a SWOG-GOG-ECOG intergroup study. Proc ASCO 1995; 14: 273
   Google Scholar
• McGuire WP, Hoskins W, Brady M, et al. Taxol and cisplatin improves outcome in advanced ovarian cancer as compared to cytoxan and cisplatin. Proc ASCO 1995; 14: 275
   Google Scholar
• Thigpen T, Vance R, Puneky L, Khansur T. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 1994; 55: S97–S107
   PubMed Web of Science ®Google Scholar
• Trimble E, Arbuck S, McGuire WP. Options for primary chemotherapy of epithelial ovarian cancer: taxanes. Gynecol Oncol 1994; 55: S114–S121
   PubMed Web of Science ®Google Scholar
• Inoue M, Fujita M, Enomoto T, Tanizawa O. Long-term follow-up of patients with advanced ovarian cancers treated with intermittent administration of combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Int J Gynecol Cancer 1995; 5: 1–7
   PubMedGoogle Scholar
• Moertel CG. Chemotherapy for colorectal cancer. N EngI J Med 1994; 330(16)1136–1141
   PubMed Web of Science ®Google Scholar
• The Advanced Colorectal Cancer Meta-analy sis Project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. JCO 1992; 10: 896–903
   Google Scholar
• Poon MA, O'Connel MJ, Wieand S, et al. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved efficacy in advanced colorectal cancer. JCO 1991; 9: 1967–1972
   PubMed Web of Science ®Google Scholar
• Jackman AL, Gibson W, Brown M, . The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694. Novel approaches to selective treatments of human solid tumours: Laboratory and clinical correlation, YM Rus-Tum, et al. Plenum Press, New York 1993; 265
   Google Scholar
• Clarke SJ, et al. Ann Oncol 1994; 5(suppl)132
   Google Scholar
• Adenis A, Cunningham D, Van Cutsem E, et al. Tomudex (ZD1694): a new active agent in the treatment of advanced colorectal cancer. Ann Oncol 1994; 5(suppl 8)189
   PubMedGoogle Scholar
• World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO, Geneva 1979, WHO Offset Publication No. 48
   Google Scholar
• Manual ofOncologic Therapeutics, RE Wittes, 1989/1990
   Google Scholar
• Aaronson NK, Ahmedazi S, Bergamot B, et al. The European Organization for Research and Treatment of Cancer QIQ-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365–376
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald J, et al. Levamisole and fluo-rouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–358
   PubMed Web of Science ®Google Scholar
• Steplewski Z, Lubeck MD, Kaprowski H. Human macrophages armed with murine immune-globulin G2a antibodies to tumors destroy human cancer cells. Science 1983; 221: 866–867
   Google Scholar
• Douillard JY, Bourdin S, LeMevel B, et al. Effect of a single dose injection of MoAb 17–1A as adjuvant treatment in high risk colorectal cancer: results of a randomized study. Poster presentation at the Conference on Molecular Approaches to Cancer Immunotherapy of the American Association for Cancer Research, Asheville, NC, Nov., 7–111993
   Google Scholar
• Riethmuller G, Schneider-Gadicke E, Schlimok G, et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' Ccolorectal carcinoma. Lancet 1994; 343: 1177–1183
   PubMed Web of Science ®Google Scholar
• Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1535–1540
   PubMed Web of Science ®Google Scholar
• Abratt RP, Bezwoda WR, Goedhals L, Hacking DJ. A phase 2 study of gemcitabine with cisplatin in patients with non-small cell lung cancer. Proc ASCO 1995, (abstract 1159)
   Google Scholar
• Burns HA, III, Anderson JS, Moore M, Green MR, et al. Gemcitabine: effective palliative therapy for pancreas cancer patients failing 5-FU. Proc ASCO 1995, (abstract 470)
   Google Scholar
• Casmichæl J, Possinger K, Philip P, Beykirch M, Kerr H, et al. Dif-luorodeoxycytidine (gemcitabine): a phase II study in patients with advanced breast cancer. Proc ASCO 1993, (abstract 57)
   Google Scholar
• Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2′2′-difluorodeoxycytidine) in patients with adenocarcinoma of pancreas. Invest New Drugs 1994; 12: 29–34
   PubMed Web of Science ®Google Scholar
• Grindey GB, Hertel LW, Plunkett W. Cytotoxicity and antitumor activity of 2′2′-difluorodeoxycytidine (gemcitabine). Cancer Invest 1990; 8: 313–318
   PubMedGoogle Scholar
• Lund B, Paaske Hansen O, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′2′-difiuorodeoxycytidine) in previously treated ovarian cancer patients. J Nat] Cancer List 1994; 86: 1530
   PubMed Web of Science ®Google Scholar
• Millward MJ, Rischin D, Toner GC, Bishop JF, et al. Activity of gemcitabine in ovarian cancer patients resistant to paclitaxel. Proc ASCO 1995, (abstract 776)
   Google Scholar
• Moore M, Andersen J, Burris H, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R, Storniolo A, Von Hoff D. A randomized trial of gemcitabine versus 5FU as first-line therapy in advanced pancreatic cancer. Proc ASCO 1995; 14: 1999, abstract 473
   Google Scholar
• Shepherd FA, Gatzemeier U, Gotfried M, Weynants P, et al. An extended phase II study of gemcitabine in non small cell lung cancer (NSCLC). Proc ASCO 1993, (abstract 1096)
   Google Scholar
• Sarosdy MF, Lamm DL, Williams RD, Moon TD, Flanigan RC, Crawford ED, Wilks NE, Earhart RH, Merritt JA. Phase I trial of oral bropirimine in superficial bladder cancer. J Urol 1992; 147: 827
   PubMedGoogle Scholar
• Sarosdy MF, Lowe BA, Schellhammer PF, Lamm DI, Graham SD, Jr., Grossman HB, See WA, Peabody JO, Moon TD, Flanigan RC, Crawford ED, Earhart RH. Bropirimine immunotherapy of bladder CIS: positive phase II results of an oral interferon inducer. J Urol 1994; 13: 304A
   Google Scholar
• Sarosdy MF, Kierum CA. Combination immunotherapy of murine transitional cell carcinoma using BCG and an interferon-inducing pyrimidinone. J Urol 1989; 142(5)1376
   PubMed Web of Science ®Google Scholar
• Legha SS, Buzaid AC. Role of recombinant interleukin-2 in combination with interferon-alfa and chemotherapy in the treatment of advanced melanoma. Semin Oncol 1993; 20(suppl 9)27–32
   PubMedGoogle Scholar
• Buzaid AC, Legha SS. Combination of chemotherapy with inter-leukin-2 and interferon-alfaforthe treatment of advanced melanoma. Semin Oncol 1994; 21(suppl 14)23–28
   PubMedGoogle Scholar
• Richards J, Mehta N, Ramming K, et al. Sequential chemoimmuno-therapy in the treatment of metastatic melanoma. J Clin Oncol 1992; 10: 1338–1343
   PubMed Web of Science ®Google Scholar
• Richards J, Mehta N, Schroeder L, Dordal A. Sequential chemother-apy/immunotherapy for metastatic melanoma. Proc Am Soc Clin Oncol 1992; 11: 346
   Google Scholar
• Hamrell MR. Inhibition of dihydrofolate reductase and cell growth by antifols in a methotrexate-resistant cell line. Oncology 1984; 41: 343
   PubMed Web of Science ®Google Scholar
• Weir E, Cashmore A, Dreyer R, et al. Pharmacology and toxicity of a potent “nonclassical” 2,4-diamino quinazoline folate antagonist, trimetrexate, in normal dogs. Cancer Res 1982; 42: 1696
   PubMed Web of Science ®Google Scholar
• O'Dwyer P, DeLap R, King S, et al. Trimetrexate: Clinical development of a nonclassical antifolate. NCI Monogr 1987; 5: 105
   PubMedGoogle Scholar
• Kamen B, Cashmore A, Dreyer R, et al. Uptake and efficacy of trimetrexate, a nonclassical antifolate in methotrexate resistant leukemia cells in vitro. Biochem Pharmacol 1984; 33: 1697
   PubMed Web of Science ®Google Scholar
• Romanini A, Li W, Colofiore J, et al. Leucovorin enhances cytotoxicity of trimetrexate/fluorouracil, but not methotrexate/fluorouracil in CCRF-CEM cells. J Natl Cancer Inst 1992; 84: 1033
   PubMed Web of Science ®Google Scholar
• Lin J, Bertino B. Update on trimetrexate, a folate antagonist with antineoplastic and antiprotozoal properties. Cancer Invest 1991; 9: 159
   PubMed Web of Science ®Google Scholar
• Jackson R, Leopold W, Hamelehle K, et al. Preclinical studies with trimetrexate: a review of conclusions and unanswered questions. Semin Oncol 1988; 15(2 suppl 2)1
   PubMed Web of Science ®Google Scholar
• Maroun J, Leiby J, Capizzi R, et al. Efficacy of trimetrexate (CI-898, TMTX) in patients with solid tumors. Clin Res 1987; 35: 529A
   Google Scholar
• Ajani J, Abbruzzese J, Faintuch J, et al. A phase II study of trimetrexate therapy for metastatic colorectal carcinoma. Cancer Invest 1990; 8: 619
   PubMed Web of Science ®Google Scholar
• Conti J, Kemeny N, Seiter K, et al. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma. J Clin Oncol 1994; 12: 695
   PubMed Web of Science ®Google Scholar
• Bruckner HW, Kalnicki S, Dalton J, Snady H, Schwartz GK, Chesser MR, Lehrer Mandeli J, Itzkowitz S, Harpaz N, Janus C. Survival following combined modality therapy for pancreatic cancer. J Clin Gastroenterol 1993; 16(3)199–203
   PubMed Web of Science ®Google Scholar
• Bruckner HW, Kalnicki S, Dalton J, Schwartz GK, Chesser MR, Mandeli J, Janus C. Combined modality therapy increasing local control of pancreatic cancer. Cancer Invest 1993; 11(3)241–246
   PubMed Web of Science ®Google Scholar
• Skillings JR, Sridhar FG, Wong C, et al. The frequency of red cell transfusion for anemia in patients receiving chemotherapy: a retrospective cohort study. Am J Clin Oncol 1993; 16: 22–25
   PubMed Web of Science ®Google Scholar
• Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990; 322: 1689–1692
   PubMed Web of Science ®Google Scholar
• Abels RI. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992; 87(suppl 1)4–11
   PubMedGoogle Scholar
• Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991; 9: 2021–2026
   PubMed Web of Science ®Google Scholar
• Bray GL, Reaman GH. Erythropoietin deficiency: a complication of cisplatin therapy and its treatment with recombinant human erythropoietin. Am J Pediatr Hematol Oncol 1991; 13: 426–430
   PubMedGoogle Scholar
• Case DC, Jr, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993; 85: 801–806
   PubMed Web of Science ®Google Scholar
• Gebbia V, Palmeri S, Valenza R, et al. The in vivo effects of recombinant human erythropoietin on cisdiamminodichloroplatinum-induced anemia in golden Syrian hamsters. In Vivo 1991; 5: 149–152
   PubMedGoogle Scholar
• Gamucci T, Thorel MF, Frasca AM, et al. Erythropoietin for the prevention of anaemia in neoplastic patients treated with cisplatin. Eur J Cancer 1993; 29A(suppl 2)S13–S14
   PubMedGoogle Scholar
• Cascinu S, Fedeli A, Fedeli SL, et al. Cisplatin-associated anaemia treated with subcutaneous erythropoietin: a pilot study. Br J Cancer 1993; 67: 156–158
   PubMed Web of Science ®Google Scholar
• Miller CB, Platanias LC, Mills SR, et al. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. J Natl Cancer Inst 1992; 84: 98–103
   PubMed Web of Science ®Google Scholar
• Henry DH, Abels RI. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: results of double-blind and open-label follow-up studies. Semin Oncol 1994; 21: 21–28
   PubMed Web of Science ®Google Scholar
• Cascinu S, Fedeli A, Del Ferro E, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994; 12: 1058–1062
   PubMed Web of Science ®Google Scholar
• Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D. Phase II study of taxol, merbarone and piroxantrone in stage IV non-small cell lung cancer: the Eastern Cooperative Oncology Group Results. J Natl Cancer Inst 1993; 85: 388–394
   PubMed Web of Science ®Google Scholar
• Murphy WK, FosseUa F, Winn RJ, Shin DM, Hynes HE, Gross HM, DaviUa E, Leimert J, Khingra H, Raber WM, Krakoff IH, Hong WK. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 1993; 85: 384–388
   PubMed Web of Science ®Google Scholar
• Gatzemeier V, Pawel JR, Heckmayer M, Neuhass R, Schluter I. Phase II study with paclitaxel in advanced inoperable non-small cell lung cancer (NSCLC)—the European experience, Lung Cancer. The Journal of the International Association for the Study of Lung Cancer 1994; 2(suppl 2)236
   Google Scholar
• Bonomi P, Finkelstein D, Ruckdeschel J, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small cell lung cancer: a study of the Eastern Cooperative Group. J Clin Oncol 1989; 7: 1602–1613
   PubMed Web of Science ®Google Scholar
• Green MR, Kreisman H, Linkart S, . Carboplatin in non-small cell lung cancers: the Cancer and Leukemia Group B experience. Carboplatin (JM-8): Current Perspectives and Future Directions, Bunn, Jr, Canetta, Ozols, Rozensweig, et al, 301–306
   Google Scholar
• Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or Carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 1990; 8: 1556–1562
   PubMed Web of Science ®Google Scholar
• Langer CJ, Leighton JC, Comis R, McAleer C, Bonjo C, O'Dwyer, Millenson M, Leonardo J, Shore S, Packer S, Litwin S, Ozols R. Paclitaxel and Carboplatin in advanced non-small cell lung cancer: toxicity, response, and survival update. Proc Am Soc Clin Oncol 1995; 14: 355, A-1080
   Google Scholar
• Hainsworth JD, Greco A. Paclitaxel administered by 1-hour infusion. Cancer 1994; 74: 1377–1382
   PubMed Web of Science ®Google Scholar
• Swenerton K, Eisenhauer E, ten Bokkel Huinink W, Myles J, Magnioni C, Van der Brug M, Kew I, Gianni L, Vermoken J, Buser K, Saduro A, Bacon M, Santabarbara P, Onetto N, Canetta R. Taxol in relapsed ovarian cancer: high vs low dose and short vs long infusion (abstract). Proc Am Soc Clin Oncol 1993; 12: 256
   Google Scholar
• Nabholtz JM, Gelmon K, Bonteubal M, et al. Randomized trial of two doses of taxol in metastatic breast cancer: an interim analysis (abstract). Proc Am Soc Clin Oncol 1993; 42: 60
   Google Scholar
• Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MM. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993; 19: 351–386
   PubMed Web of Science ®Google Scholar
• Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314–322
   PubMed Web of Science ®Google Scholar
• Venveij J, Clavel M, Chevalier B. Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind. Ann Oncol 1994; 5: 495–505
   PubMed Web of Science ®Google Scholar
• ten Bokkel Huinink WW, Prove AM, Piccart M, et al. A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. Ann Oncol 1994; 5: 527–532
   PubMed Web of Science ®Google Scholar
• Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel (Taxoter): a new highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995, in press
   PubMed Web of Science ®Google Scholar
• Rahman A, et al. Liposomal protection of Adriamycin-induced cardiotoxicity in mice. Cancer Res 1980; 40: 1532–1537
   PubMed Web of Science ®Google Scholar
• Herman EH, et al. Prevention of chronic doxorubicin cardiotoxicity in beagles by liposomal encapsulation. Cancer Res 1983; 43: 5427–5432
   PubMed Web of Science ®Google Scholar
• Gabizon A, et al. Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study. Eur J Clin Oncol 1989; 25(12)1795–1803
   PubMedGoogle Scholar
• Rahman A, et al. A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 1990; 8(6)1093–1100
   PubMed Web of Science ®Google Scholar
• Cowens JW, et al. Initial clinical (phase I) trial of TLD D-99 (doxorubicin encapsulated in liposomes). Cancer Res 1993; 53: 2796–2802
   PubMed Web of Science ®Google Scholar
• Conley BA, et al. Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin. Cancer Chemother Pharmacol 1993; 33: 107–112
   PubMed Web of Science ®Google Scholar
• vonHoff DD, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710–717
   PubMed Web of Science ®Google Scholar
• Treat J, et al. Antitumor activity of liposome-encapsulated doxo-rubicin in advanced breast cancer: Phase II study. J Natl Cancer Instil 1990; 2(21)1706–1710
   Google Scholar
• Batist G, et al. Phase II study of liposomal doxorubicin (TLCD99) in metastatic breast cancer. Proc ASCO 1992; 11: 82
   Google Scholar
• Fonseca GA, et al. Phase II study of TLC D-99 (liposomal doxorubicin) in patients (PTS) with metastatic breast carcinoma (MBC). Proc ASCO 1995; 14: 99
   Google Scholar
• Fonseca GA, et al. Decreased cardiac toxicity by TLC D-99 (liposomal doxorubicin) in the treatment of metastatic breast carcinoma (MBC). Proc ASCO 1995; 14: 99
   Google Scholar
• Jones RB, et al. A phase I-II study of intensive-dose Adriamycin for advanced breast cancer. J Clin Oncol 1987; 5: 172–177
   PubMed Web of Science ®Google Scholar
• Bronchud MH, et al. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer. Br J Cancer 1989; 60: 121–125
   PubMed Web of Science ®Google Scholar
• O'Day SJ, et al. Dose escalation of liposome-encapsulated doxorubicin (D-99) with granulocyte colony stimulating factor (G-CSF) support in patients with advanced malignancies. Proc ASCO 1994; 13: 153
   Google Scholar
• Muggia FM, Green MD. New anthracycline antitumor antibiotics. Crit Rev Oncol Hematol 1991; 11: 43–64
   PubMed Web of Science ®Google Scholar
• Gilladoga AC, Manuel C, Tan C, et al. The cardiotoxicity of Adriamycin and daunomycin in children. Cancer 1976; 37: 1070–1076
   PubMed Web of Science ®Google Scholar
• Juliano RL, Stamp D, McCullough N. Pharmacokinetics of liposome-encapsulated antitumor drugs. Biochem Pharmacol 1978; 27: 21–27
   PubMed Web of Science ®Google Scholar
• Forssen EA, Tokes ZA. A novel method for the preparation of Adriamycin liposomes: in vitro and in vivo studies. Biochem Biophys Res Commun 1979; 91: 1295–1301
   PubMed Web of Science ®Google Scholar
• Forssen EA, Tokes ZA. Use of anionic liposomes for the reduction of chronic doxorubicin induced cardiotoxicity. Proc Natl Acad Sci USA 1981; 78: 1873–1877
   PubMed Web of Science ®Google Scholar
• Todd JA, Rossow PW, Modest EJ, Tokes ZA. Liposome encapsulation enhancement of methotrexate sensitivity in a transport resistance human leukemic cell line. Biochem Pharmacol 1982; 31: 541–548
   PubMed Web of Science ®Google Scholar
• Forssen EA, Tokes ZA. Attenuation of dermal toxicity of doxorubicin by liposome encapsulation. Cancer Treat Rep 1983; 67: 401–484
   PubMedGoogle Scholar
• Forssen EA, Tokes ZA. Improved therapeutic benefits of doxorubicin by entrapment in anionic liposomes. Cancer Res 1983; 43: 546–550
   PubMed Web of Science ®Google Scholar
• Forssen E, Chan KK, Muggia FM, et al. Clinical pharmacokinetics (PK) of liposomal daunorubicin (VS103) (abstract). Proc Am Assoc Cancer Res 1990; 31: 181
   Google Scholar
• Treat J, Greenspan A, Forst D, et al. Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst 1990; 82: 1706–1710
   PubMed Web of Science ®Google Scholar
• Rahman A, Treat J, Ron JK, et al. A phase I clinical trial and pharmacokinetics evaluation of liposome encapsulated doxorubicin. J Clin Oncol 1990; 8: 1093–1100
   PubMed Web of Science ®Google Scholar
• Mauk M, Gamble R. Proc Natl Acad Sci, USA 1979; 74: 4991–4995
   Web of Science ®Google Scholar
• Huang SK, Lee K-D, Hong K, et al. Microscopic localization of sterically-stabilized liposomes in colon carcinoma-bearing mice. Cancer Res 1992; 52: 5135
   PubMed Web of Science ®Google Scholar
• Huang SK, Mayhew E, Gilani S, et al. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992; 52: 6774
   PubMed Web of Science ®Google Scholar
• Mayhew EG, Goldrosen MH, Vaage J, et al. Effects of liposome-entrapped doxorubicin on liver metastases of mouse colon carcinomas 26 and 38. J Natl Cancer Inst 1987; 78: 707
   PubMed Web of Science ®Google Scholar
• Odajnik CM, Muggia FM. Therapy of Kaposi's sarcoma: overview and analysis by clinical setting. J Clin Oncol 1985; 3: 1277–1285
   PubMed Web of Science ®Google Scholar
• Presant CA, Proffitt RT, Turner AF, Williams LH, Winsor D, Werner JL, Kennedy P, Wisemand C, Gal K, McKenna RJ, Smith JD, Bouzaglou SA, Callahan RA, Baldeschwieler J, Crossley RJ. Successful imaging of human cancer with indium-111-labeled phospholipid vesicles. Cancer 1988; 62: 905–911
   PubMed Web of Science ®Google Scholar
• Guaglianone P, Chan K, DelaFlor-Weiss E, Hanisch R, Jeffers S, Sharma D, Muggia F. Phase I and pharmacologic study of liposomal daunombicin (DaunoXome). Inv New Drugs 1994; 12: 103–110
   PubMed Web of Science ®Google Scholar
• Gill PS, Espina BM, Muggia F, Cabrales S, Tulpule A, Esplin JA, Liebman HA, Forssen E, Ross ME, Levine AM. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13: 996–1003
   PubMed Web of Science ®Google Scholar
• Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer 1994; 54: 987–992
   Web of Science ®Google Scholar
• Mickisch GH, Rahman A, Pastan I, et al. Increased effectiveness of liposome-encapsulated doxorubicin in multidrug-resistant-transgenic mice compared with free doxorubicin. J Natl Cancer Inst 1992; 84: 804
   PubMed Web of Science ®Google Scholar
• Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Taso D, Yehoshua Z, Muggia FM, Gabizon A. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13: 1779–1785
   Google Scholar
• Tokes ZA, Smith MI, Forssen EA, Dubeau L, Jones P, Muggia FM. Nanosphere-coupled and liposome-entrapped anthracyclines: potential intracavity treatment of human bladder carcinoma. Proc Am Assoc Cancer Res 1989; 30: 601, abstract 2391
   Google Scholar
• Slichenmyer WJ, Rowinsky EK, Donehower RC, et al. The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst 1993; 85: 271–291
   PubMed Web of Science ®Google Scholar
• Kingsbury WD, Boehm JC, Jakas DR, et al. Synthesis of water-soluble (aminoalkyl) camptothecin analogues: inhibition of topoisomerase I and antitumor activity. J Med Chem 1991; 34: 98–107
   PubMed Web of Science ®Google Scholar
• Hertzberg RP, Caranfa MJ, Holden KG, et al. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. JMed Chem 1989; 32: 715–717
   PubMed Web of Science ®Google Scholar
• Rowinsky EK, Adjei A, Donehower RC, et al. A phase land pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. JClinOncol 1994; 12: 2193–2203
   Web of Science ®Google Scholar
• Grochow LB, Rowinsky EK, Johnson R, et al. Pharmacokinetics and pharmacodynamics of topotecan. Drug Metab Dispos 1992; 20: 706–712
   PubMed Web of Science ®Google Scholar
• Schiller JH, Kim K, Johnson D. Phase II study of topotecan in extensive stage small cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: 330
   Google Scholar
• Ardizzoni A, Hansen H, Dombemowsky P, et al. Phase II study topotecan in pretreated small cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: 336
   Google Scholar
• Kudelka A, Edwards C, Freedman R, et al. An open phase II study to evaluate the efficacy and toxicity of topotecan administered intravenously as 5 daily infusions every 21 days to women with advanced epithelial ovarian carcinoma. Proc Am Soc Clin Oncol 1993; 12: 259
   Google Scholar
• Armstrong D, Rowinsky E, Donehower RC, et al. Phase II study of topotecan as salvage therapy in epithelial ovarian cancer. Proc Am Soc Clin Oncol 1995; 14: 275
   Google Scholar
• Eisenhauer EA, Wainman G, Boos G, et al. Phase n trials of topotecan in patients (pts) with malignant glioma and soft tissue sarcoma. Proc Am Soc Clin Oncol 1994; 13: 175
   Google Scholar
• Perez-Soler R, Fossella FV, Glisson BS, et al. Phase II study of topotecan in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1994, in press
   PubMed Web of Science ®Google Scholar
• Wietz JJ, Jung S-H, Marschke RF, et al. Randomized phase II trial of two schedules of topotecan for the treatment of advanced stage non-small cell lung carcinoma (NSCLC): a North Central Cancer Treatment Group (NCCTG) trial. Proc Am Soc Clin Oncol 1995; 14: 348
   Google Scholar
• Creemers GJ, Schellens J HM, Planting A ST, et al. Cumulative myelosuppression of topotecan (T) administered as a 21-day continuous infusion in patients with colorectal cancer. Proc Am Soc Clin Oncol 1995; 14: 167
   Google Scholar
• Sugarman SM, Ajani JA, Daugherty K, et al. A phase II trial of topotecan (TPT) for the treatment of advanced, measurable colorectal cancer. Proc Am Soc Clin Oncol 1994; 13: 225
   Google Scholar
• Johnson RK, Hertzberg RP, Kingsbury WD, et al. Preclinical profile of SK&F 104864, a water soluble analogue of camptothecin. Proceedings of the Sixth NCI-EORTC Symposium on New Drugs in Cancer Therapy 1989; 301
   Google Scholar
• Hendricks CB, Rowinsky EK, Grochow LB, et al. Effect of P-glyco-protein expression on accumulation and cytotoxicity of topotecan (SK&F 104864), anew camptothecin analog. Cancer Res 1992; 52: 2268
   PubMed Web of Science ®Google Scholar
• Mattem MR, Hofmann GA, Polsky RM, et al. In vitro and in vivo effects of clinically important campothecin analogues in multidrug-resistant cells. Oncology Res 1993; 5: 467–474
   PubMed Web of Science ®Google Scholar
• Rowinsky E, Sartorius S, Grochow L, et al. Phase I and phar-macologic study of topotecan, an inhibitor of topoisomerase I, with granulocyte colony-stimulating factor (G-CSF): toxicologic differences between concurrent and post-treatment G-CSF administration. Proc Am Soc Clin Oncol 1992; 11: 116
   Google Scholar
• Rowinsky EK, Adjei A, Donehower RC, et al. A phase I and pharmacodynamic study of the topoisomerase I inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol 1994; 12: 2193
   PubMed Web of Science ®Google Scholar
• Cheng MF, Chatterjee S, Berger N. Schedule-dependent cytotoxicity of topotecan alone and in combination chemotherapy regimens. Oncology Res 1994; 6: 269
   PubMed Web of Science ®Google Scholar
• Johnson R, McCabe F, Yu Y. Combination regimens with topotecan in animal tumor models. Ann Oncol 1992; 3(suppl 1)85
   PubMedGoogle Scholar
• Rowinsky E, Grochow L, Kaufmann S, et al. Sequence-dependent effects of topotecan and cisplatin in a phase I and pharmacokinetic study. Proc Am Soc Clin Oncol 1994; 13: 142
   Google Scholar
• Shimada Y, Yoshino M, Wakui A, Nakao I, Fatatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N, the CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993; 11: 909–913
   PubMed Web of Science ®Google Scholar
• Rothenberg ML, Eckardt JR, Bums HA, III, Nelson J, Kuhn JG, Chen SF, Hilsenbeck SG, Clark GM, Fields SM, Rodriguez GI, Weiss GR, Smith LS, Thurman AM, Eckhardt SG, Rinaldi DA, Perez E, Von Hoff DD. Irinotecan (CPT-11) as second-line therapy for pts with 5-FU-refractory colorectal cancer. Proc ASCO 1994; 13: 198, abstract 578
   Google Scholar
• Pilot HC, Wender D, O'Connell MJ, Wieand HS, Mailliard JA. A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: a North Central Cancer Treatment Group study. Proc ASCO 1994; 13: 197, abstract 573
   Google Scholar
• Bugat R, Rougier P, Brunei P, Douillard JY, Ychou M, Marty M, Bonneterre J, Ganem G, Seitz JF, Merrouche H, Namer M, Conroy T, Burky F, Mousseau M. Clinical efficacy of CPT-11 in patients with inoperable advanced colorectal cancer: results of a multicentric open phase II study. Proc 5th Intl Congr Anti-Cancer Chemother 1995; 5: 288, abstract S775
   Google Scholar
• Conti JA, Kemeny N, Saltz L, Tong W, Chou TC, Pulliam M. Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer. Proc ASCO 1994; 13: 195, abstract 565
   Google Scholar
• Negoro S, Fukuoka M, Niitani H, Suzuki A, Nakabayashi T, et al. A phase II study of CPT-11, a camptothecin derivative, in patients with primary lung cancer. Jpn J Cancer Chemother 1991; 19: 1013–1019
   Google Scholar
• Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T, for the CPT-11 Lung Cancer Study Group. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. J Clin Oncol 1992; 10: 16–20
   PubMed Web of Science ®Google Scholar
• Douilliard JY, Ibrahim N, Riviere A, Spaeth D, Chomy P, Soussan K, Mathieu-Boué A. Phase II study of CPT-11 (ironotecan) in non small cell lung cancer. Proc ASCO 1995; 14: 365, abstract 1118
   Google Scholar
• Masuda N, Fukuoka M, Takada M, Kusunoli Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S. CPT-11 in combination with cisplatin for advanced non-small cell lung cancer. J Clin Oncol 1992; 10: 1775–1780
   PubMed Web of Science ®Google Scholar
• Masuda N, Kukuoka M, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Hirashima T, Tamanoi M, Nitta T, Yana T, Negoro S, Takifuji N, Takada M. Phase I study of irinotecan and cisplatin with granulocyte colony-stimulating factor support for advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 90–96
   PubMed Web of Science ®Google Scholar
• Nitta T, Takada M, Hirashima T, Tamanoi M, Masuda N, Kudoh S, Kusunoki Y, Matsui K, Nakagawa K, Takifuji N, Negoro S, Fukuoka M. Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Proc AACR 1993; 34: 206, abstract 1227
   Google Scholar
• Mori K, Suga U, Kishiro I., Ohta S, Tominaga K. A phase I study of CPT-11 and cisplatin (5-day continuous infusion) for advanced non-small cell lung cancer. Proc ASCO 1994; 13: 366, abstract 1234
   Google Scholar
• Shinkai T, Arioka H, Kunikane H, Eguchi K, Sasaki Y, Tamaura T, Ohe Y, Oshita F, Nishio M, Karato A, Okamoto H, Nakashima H, Ohmatsu H, Shiraishi J, Nomura N, Saijo N. Phase I clinical trial of irinotecan (CPT-11), 7-ethyl-10–[4–1-piperidino)-1-piper-idino] carbonyloxy-camptothecin, and cisplatin in combination with fixed dose vindesine in advanced non-small cell lung cancer. Cancer Res 1994; 54: 2636–2642
   PubMed Web of Science ®Google Scholar
• Karato S, Sasaki Y, Shinkai T, Eguchi K, Tamura T, Ohe Y, Oshita F, Nishio M, Kunikane H., Arioka H., Ohmatsu H, Nakashima H, Shiraishi J, Saijo N. Phase I study of CPT-11 and etoposide in patients with refractory solid tumors. J Clin Oncol 1993; 11: 2030–2035
   PubMed Web of Science ®Google Scholar
• Masuda N, Fukuoka M, Kudoh S, Matsui K, Kusunoki Y, Takada M, Nakagawa K, Hirashima T, Tsukada H, Yana T, Yoshikawa A, Kubo A, Matsuura E, Nitta T, Takifuji N, Terakawa K, Negoro S. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony stimulating factor support for advanced lung cancer. J Clin Oncol 1994; 12: 1833–1841
   PubMed Web of Science ®Google Scholar
• Abigerges D, Armand J-P, Chabot GG, et al. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea. J Natl Cancer Inst 1994; 86: 446–449
   PubMed Web of Science ®Google Scholar
• Abigerges D, Chabot GG, Armand J-P, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210–221
   PubMed Web of Science ®Google Scholar
• Sakata Y, Suzuki H, Kamataki T. Preventive effect of TJ-14, a Kampo medicine, on diarrhea induced by irinotecan. Proc ASCO 1994; 13: 456, abstract 1578
   Google Scholar
• Hagipantelli R, Saliba F, Misset JL, Giacchetti S, Brain E, Bertheaull-Cvilokovic F, Vassal G, Bonnay M, Baslian G, Cole C, Mahjoubi M, Hérait P, Cvitokovic E. Palhophysiology and therapy of irinotecan (CPT-11) induced delayed onset diarrhea: a prospective assessmenl. Proc ASCO 1995; 14: 464, abstracl 1499
   Google Scholar
• Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niilani H, Taguchi T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small cell lung cancer. J Natl Cancer Insl 1991; 93: 1164–1168
   Google Scholar
• Cohen AM, Shank B, Friedman MA. Colorectal cancer. Cancer. Principles and Practices of Oncology, VT DeVita, S Hellman, SA Rosenberg. Lippincott, Philadelphia 1989; 895–964
   Google Scholar
• Bruckner HW, Motwani BT. Chemotherapy of advanced cancers of the colon and rectum. Semin Oncol 1991; 18: 443–461
   PubMed Web of Science ®Google Scholar
• Lokich J, Bothe A, Fine N, et al. Phase I study of protracted venous infusion of 5-FU. Cancer 1981; 48: 2565–2568
   PubMed Web of Science ®Google Scholar
• Hansen R, Quebberman E, Ausman R, et al. Continuous systemic 5-FU (5-FU) infusion in advanced colorectal cancer: rsults of 91 patients. J Surg Oncol 1989; 40: 177–181
   PubMed Web of Science ®Google Scholar
• Grem. Fluorinated pyrmidines. Cancer Chemotherapy Principles and Practice, BA Chabner, JA Collins. Lippincott, Philadelphia 1990; 180–224
   Google Scholar
• Cohen JL, Irwin LE, Marshall GJ, Darvey H, Bateman JR. Clinical pharmacology of oral and intravenous 5-FU (NSC 19893). Cancer Chemother Rep 1974; 58: 723–731
   PubMedGoogle Scholar
• Heggie GD, Sommadossi JP, Cross DS, Hustler WJ, Drasio RB. Metabolism of 5-FU in cancer patients with quantitation of fluorouracil catabolites in plasma, urine, and bile over time. Cancer Res 1987; 47: 2203–2206
   PubMed Web of Science ®Google Scholar
• Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T. Experimental neurotoxicity of 5-FU and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoracetic acid and alpha-fluoro-bela-alanine. Acta Neuropathol 1990; 91: 66–73
   Google Scholar
• Porter D JT, Chestnut WG, Merrill BM, Spector T. Mechanism-based inactivation of dihydropyrimidine dehydrogenase by 5-ethyluracil. J Biol Chem 1992; 267: 5236–5242
   PubMed Web of Science ®Google Scholar
• Baccanari DP, Davis DT, Knick VC, Spector T. 5-Ethyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-FU. Proc Natl Acad Sci USA 1993; 90: 11064–11068
   PubMed Web of Science ®Google Scholar
• Shousong C, Yousef MR, Spector T. 5-Ethyluracil (776C85): modulation of 5-FU efficacy and therapeutic index in rates bearing advanced colorectal carcinoma. Cancer Res 1994; 54: 1507–1510
   PubMed Web of Science ®Google Scholar
• Bums H, Schilsky R, Fields S, et al. Initial phase I trial of the dihydroyprimidine dehydrogenase inactivator 5-ethynluracil (776C85) plus 5-fluorouracil. Proc Am Soc Clin Oncol 1995; 14: 171
   Google Scholar
• Adjei AA, Doucette M, Spector T, et al. The dihydropyrimidine dehydrogenase (DPD) inhibitor 5-ethynluracil (776C85) permits reliable oral dosing of 5-fluorouracil (5-FU) and prolongs its half-life (T1/2). Proc Am Soc Clin Oncol 1995; 14: 459
   Google Scholar
• Fisher B. Laboratory and clinical research in breast cancer—a personal adventure: the David A. Karnofsky Memorial Lecture. Cancer Res 1980; 40: 3863–3874
   PubMed Web of Science ®Google Scholar
• Fisher B, et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985; 312: 674–681
   PubMed Web of Science ®Google Scholar
• Fisher B, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989; 320: 822–828
   PubMed Web of Science ®Google Scholar
• Fisher B, et al. L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a report of early findings. N Engl J Med 1975; 292: 114–122
   Google Scholar
• Fisher B, et al. L-Phenylalanine mustard (L-PAM) in the management of primary breast cancer: a update of earlier findings and a comparison with those utilizing L-PAM plus 5-fluorouracil (5-FU). Cancer 1977; 39: 2883–2903
   PubMed Web of Science ®Google Scholar
• Fisher B, et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981; 305: 1–6
   PubMed Web of Science ®Google Scholar
• Fisher B, et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from NSABPB-16. J clin Oncol 1990; 8: 1005–1018
   PubMed Web of Science ®Google Scholar
• Fisher B, et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with six months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from NSABP B-15. J Clin Oncol 1990; 8: 1483–1496
   PubMed Web of Science ®Google Scholar
• Fisher B, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Eng J Med 1989; 320: 479–484
   PubMed Web of Science ®Google Scholar
• Fisher B, et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. N Engl J Med 1989; 320: 473–478
   PubMed Web of Science ®Google Scholar
• Fisher B. The evolution of paradigms for the management of breast cancer: a personal perspective. Cancer Res 1992; 52: 2371–2383
   PubMed Web of Science ®Google Scholar
• Fisher B, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993; 328: 1581–1586
   PubMed Web of Science ®Google Scholar
• Smith IE, Jones AL, O'Brien M ER, et al. Primary medical (neo-ad-juvant) chemotherapy for operable breast cancer. Eur J Cancer 1993; 29A: 1796–1799
   PubMed Web of Science ®Google Scholar
• Hortobagyi GN, Ames GR, Buzdar FC, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery and radiation therapy. Cancer 1988; 62: 2507–2516
   PubMed Web of Science ®Google Scholar
• Anderson E DC, Forrest A PM, Hawkins RA, et al. Primary systemic therapy for operable breast cancer. Br J Cancer 1991; 63: 561–566
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Veronesi U, Brambilla C, et al. Primary chemotherapy to avoid mastectomy with diameters of three centimeters or more. J Natl Cancer Inst 1990; 82: 1539–1545
   PubMed Web of Science ®Google Scholar
• Jacquillat C, Weil M, Baillet F, et al. Results of neoadjuvant chemotherapy and radiation therapy in the breast-conserving treatment of 250 patients with all stages of infiltrative breast cancer. Cancer 1990; 66: 119–129
   PubMed Web of Science ®Google Scholar
• Findlay M, Cunningham D, Norman A, et al. A phase II study in advanced gastroesophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 1994; 5: 609–606
   PubMed Web of Science ®Google Scholar
• Jones AL, Smith IE, O'Brien M ER, et al. Phase II study of continuous infusional 5-FU with epirubicin and cisplatin (infusional ECF) in patients with metastatic and locally advanced breast cancer: an active new regimen. J Clin Oncol 1994; 12: 1259–1265
   PubMed Web of Science ®Google Scholar
• Powles TJ, Hickish TF, Makris A, et al. Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer. J Clin Oncol 1995; 13: 547–552
   PubMed Web of Science ®Google Scholar
• Scholl SM, Fourquet A., Asselain B, et al. Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer 1994; 30A: 645–652
   PubMed Web of Science ®Google Scholar
• Long-Term Tamoxifen Treatment for Breast Cancer, VC Jordan. University of Wisconsin Press, Madison 1994
   Google Scholar
• Jordan VC. Tamoxifen for breast cancer prevention. Proc Soc Expt Biol Med 1995; 208: 144–149
   PubMed Web of Science ®Google Scholar
• Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen. Eur J Cancer 1994; 30A: 1714–1721
   PubMed Web of Science ®Google Scholar
• Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: clearing up a controversy. Clin Cancer Res, in press
   Google Scholar
• Abrahamova J, Bustova I, Malec V, et al. Results of clinical study: NAVELBINE (NVB) and doxorubicin (DOX) combination in advanced breast cancerpreviously untreated. Presented at Fifth International Congress on Anti-Cancer Chemotherapy(Neo-Adjuvant, Adjuvant and Experimental), Paris, January 31-February 3, 1995
   Google Scholar
• Blajman C, Balbiani L, Block J, et al. NAVELBINE (N) plus adriamycin (A) vs FAC in advanced breast cancer (ABC). Proc ASCO 1993; 12: 92
   Google Scholar
• Coppola F, Balbiani L, Blajman C, et al. Vinorelbine (VNB) containing regimens in three different schedules for the treatment of advanced breast cancer (ABC). Proc ASCO 1994; 13: 85
   Google Scholar
• Hochster H, Vogel C, Blumenreich M, et al. A U.S. multicenter phase II study of NAVELBINE (NVB) and doxorubicin (DOX) as first line chemotherapy of metastatic breast cancer. Breast Cancer Res Treat 1994; 32: 93
   Google Scholar
• Ibrahim N, Hortobagyi GN, Valero V, et al. Phase I study of vinorelbine (NVB; NAVELBINE) and paclitaxel (PTX) by simultaneous (sim) 3-hour (H) infusion (inf) for untreated metastatic breast cancer (MBC). Proc AACR 1995; 36: 242
   Google Scholar
• Kardinal CG, Cole JT, Gralla RJ, et al. NAVELBINE (vinorelbine) and mitomycin C: combination therapy in advanced breast cancer. Proc ASCO 1995; 14: 131
   Google Scholar
• Marty M, Extra JM, Dieras V, et al. A review of the antitumor activity of vinorelbine in breast cancer. Drugs 1992; 44(suppl 4)29–35
   PubMedGoogle Scholar
• Ray-Coquard I, Blay JY, Bachelot T, et al. Continuous IV infusion of vinorelbine (VNB) and bolus cisplatin (CDDP) (CIVIC regimen) an efficient regimen in hormono resistant metastatic breast cancer (MBC), after failure of anthracyline and/or paclitaxel. Proc ASCO 1995; 14: 137
   Google Scholar
• Scheithauer W, Kornek G, Haider K, et al. Effective second line chemotherapy of advanced breast cancer with NAVELBINE and mitomycin C. Breast Cancer Res Treat 1993; 31: 49–53
   Google Scholar
• Van Praagh I, Leduc B, Feillel V, et al. Neoadjuvant VEM chemotherapy regimen for operable breast cancer: results of a co-operative study of 69 patients. Proc ASCO 1995; 14: 136
   Google Scholar
• Vogel C, Hochster H, Blumenreich M, et al. A US multicenter phase II study of IV NAVELBINE (NVB) and 5-fluorouracil (5FU) as first line treatment of patients with advanced breast cancer (ABC). Proc ASCO 1995; 14: 91
   Google Scholar
• Pienta KJ, Lehr JE. Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol 1993; 149: 1622–1625
   PubMed Web of Science ®Google Scholar
• Pienta KJ, Naik H, Akhtar A, Yamazaki K, Replogle T, Lehr J, Donat TL, Tail L, Hogan V, Raz A. Inhibition of spontaneous rat prostate cancer metastasis by oral administration of modified citrus pectin. J Natl Cancer Inst 1995; 87: 348–353
   PubMed Web of Science ®Google Scholar
• Pienta KJ, Redman BG, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE. A combination of oral estramustine and oral etoposide for the treatment of hormone refractory prostate cancer. J Clin Oncol 1994; 12: 2005–2012
   PubMed Web of Science ®Google Scholar
• Pienta KJ, Redman BG, Hussain M, Esper PS, Flaherty LE. Inhibition of prostate cancer growth by estamustine and etoposide. Cancer 1995; 75: 1920–1926
   Web of Science ®Google Scholar
• Partin AW, Yoo J, Carter HB, et al. The use of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage in men with localized prostate cancer. J Urol 1993; 149: 110
   Google Scholar
• Rosen MA, Goldstone L, Lapin S, Wheeler T, Scardino PT. Frequency and location of extracapsular extension and positive surgical margins in radical prostatectomy specimens. J Urol 1992; 148: 331
   PubMed Web of Science ®Google Scholar
• Bigg SW, Kavoussi LR, Catalona WS. Role of nerve sparing radical prostatectomy forclinical stage B2 prostatecancer. J Urol 1990; 144: 1420
   PubMedGoogle Scholar
• Jones E, Resection C. Margin status in radical prostatectomy specimens: relationship to type of operation, tumor size, tumor grade and local tumor extension. J Urol 1990; 144: 89
   PubMed Web of Science ®Google Scholar
• Trapasso JG, deKernion JB, Smith RB, Dorey F. The incidence and significance of detectable levels of serum PSA after radical prostatectomy. J Urol 1994; 152: 1816
   PubMedGoogle Scholar
• Lange PH, Ercole CJ, Vessella RL. Serum prostatic specific antigen in the management of patients after radical prostatectomy. J Urol 1988; 139(part 2)607A
   PubMedGoogle Scholar
• Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is PSA of clinical significance in evaluating outcome after radical prostatectomy. J Urol 1993; 149: 516
   PubMed Web of Science ®Google Scholar
• Bruchovsky N. The metabolism of testosterone and dihydrotestosterone in an androgen-dependent tumor: a possible correlation between dihydrotestosterone and tumor growth in vivo. Biochem J 1972; 127: 561
   PubMed Web of Science ®Google Scholar
• Kerr J FR, Winterford CR, Harmon BV. Apoptosis: Its significance in cancer and cancer therapy. Cancer 1994; 73: 2013
   PubMed Web of Science ®Google Scholar
• Bruchovsky N, Rennie PS, Coldman AJ, Goldenberg SL, To M, Lawson D. Effects of androgen withdrawal on the stem cell population of the Shionogi carcinoma. Cancer Res 1990; 50: 2275
   PubMed Web of Science ®Google Scholar
• van Weerden WM, van Kreuningen A, Elissen N MJ, et al. Castration induced changes in morphology, androgen levels, and proliferation activity of human prostate tissue grown in athymic nude mice. The Prostate 1993; 23: 149
   PubMed Web of Science ®Google Scholar
• Buttyan R, Olsson CA, Pintar J, et al. Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol 1989; 9: 3473
   PubMed Web of Science ®Google Scholar
• Macfarlane MT, Abi-Aad A, Stein A, Danella J, Belldegrun A, deKernion JB. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol 1993; 150: 132
   PubMed Web of Science ®Google Scholar
• Oesterling JE, Andrews PE, Suman VJ, Zincke H, Myers RP. Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 1992; 149: 779
   Web of Science ®Google Scholar
• Schulman CC. Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review. The Prostate 1994; 5: 9
   PubMedGoogle Scholar
• Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF. The role of neoadjuvant hormonal manipulation in localized prostate cancer. Cancer 1993; 71: 1031
   PubMed Web of Science ®Google Scholar
• Labrie F, Cusan L, Gomez JL, et al. Down-staging of early stage prostate cancer: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1995; 44: 29
   Web of Science ®Google Scholar
• Goldenberg SL, Klotz LH, Jewit M AS, Canadian Urologic Oncology Group. Randomized controlled study of neoadjuvant reversible androgen withdrawal therapy with cyproterone acetate in the surgical management of localized prostate cancer. J Urol 1995, in press
   PubMedGoogle Scholar
• Goldenberg SL, Bruchovsky N, Gleave ME, Sullivan LD, Akakura K. Intermittent androgen suppression in the treatment of prostalic carcinoma: a preliminary report. Urology 1995, in press
   Web of Science ®Google Scholar
• Lin M-F, Garcia-Arenas R, Kawachi M, Lin FF. Regulation of the expression of prostatic acid phosphatase in LNCaP human prostate carcinoma cells. Cell Mol Biol Res 1994; 39: 739
   Google Scholar
• Gleave ME, Hsieh JT, Wu H-C, et al. Serum PSA levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992; 52: 1598
   PubMed Web of Science ®Google Scholar
• Moreno JG, Croce CM, Fischer R, Monne M, Vihko P, Mulholland SG, Gomella LG. Detection of hematogenous micrometastases in patients with prostate cancer. Cancer Res 1992; 52: 6110–6112
   PubMed Web of Science ®Google Scholar
• Katz AE, Olsson CA, Raffo AJ, Cama C, Perlman H, Seaman E, O'Toole KM, McMahon D, Benson MC, Butlyan R. Molecular staging of prostate cancer with the use of an enchanced reverse transcriptase-PCR assay. Urology 1994; 43: 765–775
   PubMed Web of Science ®Google Scholar
• Katz AE, deVries GM, Begg MD, Raffo AJ, Cama C, O'Toole K, Buttyan R, Benson MC, Olsson CA. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995; 75: 1642–1648
   PubMed Web of Science ®Google Scholar
• Deguchi T, Doi T, Ehara H, Ito S, Takahashi Y, Nishino Y, Fujihiro S, Kawamura T, Komeda H, Horie M, Kaji H, Shimokawa K, Tan-Aka T, Kawada Y. Detection of micrometastatic prostate cancer cells in lymph nodes by reverse transcriptase-polymerase chain reaction. Cancer Res 1993; 53: 5350–5354
   PubMed Web of Science ®Google Scholar
• Wood D PJ, Banks ER, Humphreys S, McRoberts JW, Rangnekar VM. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994; 74: 2533–2540
   PubMed Web of Science ®Google Scholar
• Vessella R, Stray J, Arfman E, Ellis W, Lange P. Reverse transcription polymerase chain reaction (RT-PCR) detects metastatic prostate cancer cells in lymph nodes, blood and potentially in bone marrow using PSA-mRNA as template. J Urol 1994; 151: 412A
   Google Scholar
• Israeli RS, Powell CT, Fair WR, Heston W DW. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993; 53: 227–230
   PubMed Web of Science ®Google Scholar
• Israeli RS, Powell CT, Corr JG, Fair WR, Heston W DW. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807–1811
   PubMed Web of Science ®Google Scholar
• Cama C, Olsson CA, Raffo AJ, Perlman H, Buttyan R, O'Toole K, McMahon D, Benson MC, Katz AE. Molecular staging of prostate cancer. II. a comparison of the application of an enhanced reverse transcriptase polymerase chain reaction assay for prostate specific antigen versus prostate specific membrane antigen. J Urol 1995; 153: 1373–1378
   PubMed Web of Science ®Google Scholar
• Seiden MV, Kantoff PW, Krithivas K, Propert K, Bryant M, Haltom E, Gaynes L, Kaplan I, Bubley G, DeWolf W, Sklar J. Detection of circulating tumor cells in men with localized prostate cancer. J Clin Oncol 1994; 12: 2634–2639
   PubMed Web of Science ®Google Scholar
• Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, Zhang Z-F, Roasai J. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995; 13: 1195–1200
   PubMed Web of Science ®Google Scholar
• Israeli R, Miller WH, Su SL, Samadi DS, Powell T, Heston W DW, Wise GJ, Fair WR. Sensitive detection of prostatic hematogeneous tumor cell dissemination using prostate specific antigen and prostate specific membrane-derived primers in the polymerase chain reaction. J Urol 1994; 153: 573–577
   Web of Science ®Google Scholar
• Prehn RT. Cancer Res 1991; 51: 2
   PubMed Web of Science ®Google Scholar
• O'Reilly MS, et al. Cell 1995; 79: 315
   Web of Science ®Google Scholar
• Holmgren L, et al. Nature Medicine 1995; 1: 149
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1995; 1: 27–31
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis. Molecular Basis of Cancer, J Mendelsohn, PM Howley, MA Israel, LA Liotta. WB Saunders. 1995; 206–232
   Google Scholar
• Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Medicine 1995; 1: 149–153
   PubMed Web of Science ®Google Scholar
• O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79: 315–328
   PubMed Web of Science ®Google Scholar
• Teicher BA, Holden SA, Ara G, Alvarez-Sotomayor E, Huang ZD, Chen Y-N, Brem H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57: 920–925
   PubMed Web of Science ®Google Scholar
• Forastiere AA, Takasugi BJ, Baker SJ, Wolf GT, Kudla-Hatch V. High-dose cisplatin in advanced head and neck cancer. Cancer Chemother Pharmacol 1987; 19: 155–158
   PubMed Web of Science ®Google Scholar
• Planting A ST, de Mulder P HM, de Graeff, et al. Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck, Submitted for publication
   Google Scholar
• Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung. Cancer. Principles and Practice of Oncology, 4th ed, VT DeVita, S Hellman, SA Rosenberg. JB Lippincott, Philadelphia 1993; 673–723
   Google Scholar
• Feigal EG, Christian M, Cheson B, et al. New chemotherapeutic agents in non-small cell lung cancer. Semin Oncol 1993; 20: 185–201
   PubMed Web of Science ®Google Scholar
• Hertel LW, Kroin JS, Misner JW, et al. Synthesis of 2-deoxy-2′,2′-difluoro-D-ribose and 2-deoxy-2′,2′-difluoro-D-ribofuranosyl nucleosides. J Org Chem 1988; 53: 2406–2409
   Web of Science ®Google Scholar
• Hertel LW, Boder GB, Kroin JS, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 1990; 50: 4417–4422
   PubMed Web of Science ®Google Scholar
• Abbruzzese JL, Grunewald R, Weeks EA, et al. Phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491–498
   PubMed Web of Science ®Google Scholar
• Fossella FV, Lippman S, Pang A, et al. Phase I/II study of gemcitabine by 30 minute weekly intrvenous infusion × 3 weeks every 4 weeks for non-small cell lung cancer. Proc Am Soc Clin Oncol 1993; 12: 326
   Google Scholar
• Abbruzeese JL, Pazdur R, Ajani J, et al. A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 456
   Google Scholar
• Casper ES, Green MR, Brown DP, et al. Phase II trial of gemcitabine in patients with pancreatic cancer. Proc Am Soc Clin Oncol 1991; 10: 440
   Google Scholar
• Tonato M. Gemcitabine: Novel Combination of Efficacy and Tolerability. Proc Eur Conf Clin Oncol 7 Satellite Symp, JerusalemIsrael, November, 1993, 14–16, Gemcitabine safety overview
   Google Scholar
• Anderson H, Thatcher N, Walling J, et al. Gemcitabine and palliation of symptoms in non-small cell lung cancer. Proc Am Soc Clin Oncol 1994; 13: 367
   Google Scholar
• Negoro S, Fukuoka M, Kurita Y, et al. Results of phase II studies of gemcitabine in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1994; 13: 367
   Google Scholar
• Shepherd FA, Gatzemeier U, Gotfried M, et al. An extended phase II study of gemcitabine in non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1993; 12: 330
   Google Scholar
• Abratt RP, Bezwoda WR, Falkson G, et al. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1535–1540
   PubMed Web of Science ®Google Scholar
• Bergerat SP, Drewinko B, Corry P, et al. Synergistic lethal effect of cis-dichloroammineplatinum and 1-b-D-arabinofuranosylcytosine. Cancer Res 1981; 41: 25–30
   PubMed Web of Science ®Google Scholar
• Peters GJ, Bergman AM, Ruiz van Haperen V WT, et al. Schedule dependency of the synergism between the combination of cisplatin and gemcitabine in resistant A2780 human ovarian cancer cell lines. Ann Oncol 1994; 5(suppl 5)82
   Google Scholar
• Braakhuis BJ, Ruiz van Haperen V WT, Bergman AM, et al. Pre-clinical in vivo evaluation of the combination of 2é, 2é-difhiorode-oxycytidine and cisplatin. Ann Oncol 1994; 5(suppl 5)82
   Google Scholar
• Sandier AB, Ansari R, McClean J, et al. A Hoosier Oncology Group phase II study of gemcitabine plus cisplatin in non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 357
   Google Scholar
• Stewart WP, Dunlop DJ, Cameron C, et al. Phase I/II study of cisplatin in combination with gemcitabine in non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 351
   Google Scholar
• Crino L, Scagliotti G, Marangolo M, et al. Cisplatin-gemcitabine combination in non-small cell lung cancer: a phase II study. Proc Am Soc Clin Oncol 1995; 14: 352
   Google Scholar
• Abratt RP, Bezwoda WR, Goedhals L, et al. A phase II study of gemcitabine with cisplatin in patients with non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 375
   Google Scholar
• Shepherd F, Cormier Y, Burkes R, et al. Modified continual reassessment methodology: a superior way to assess toxicity in a phase I study of gemcitabine and cisplatin for non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 358
   Google Scholar
• Carmichael J, Allerheiligen S, Walling J. A phase I/II study of gemcitabine and carboplatin in NSCLC. Proc Am Soc Clin Oncol 1995; 14: 351
   Google Scholar
• Eberhard W, Wilke H, Manegold CH, et al. Phase I dose finding study of gemcitabine and ifosfamide in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1995; 14: 351
   Google Scholar
• Warrell R PJ, de The H, Wang W-Y, Degos L. Acute promyelocytic leukemia. New Engl J Med 1993; 329: 177–189
   PubMed Web of Science ®Google Scholar
• Andreeff M, Stone R, Michaeli J, Young CW, Tong WP, Sogoloff H, Ervin T, Kufe D, Rifkind RA, Marks PA. Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent. Blood 1992; 80: 2604–2609
   PubMed Web of Science ®Google Scholar
• Samid D, Shack D, Liu S, Hudgins L, Prasanna B, Danielpour P, Qian DS, Myers CE. Phenylacetate and related nontoxic differentiation inducers in treatment of prostate, brain and skin cancer. Proc Am Assoc Cancer Res 1993; 34: 377
   Google Scholar
• Huang Y, Waxman S. Enhanced apoptosis in leukemia cells following treatment with combination fluoropyrimidines and differentiation inducers. Mol Cell Diff 1994; 2: 83–100
   Google Scholar
• Chen A, Licht JD, Wu Y, Bellinger N, Scher W, Waxman S. Retinoic acid is required for and potentiates differentiation of acute promyelocytic leukemia cells by nonretinoid agents. Blood 1994; 84: 2122–2129
   PubMed Web of Science ®Google Scholar
• Fields KK, Elfenbein GJ, Saleh RA, et al. Ifosfamide, carboplatin, and etoposide for induction and high-dose chemotherapy: Focus on breast cancer and lymphoma. Hematol Oncol 1992; 10: 61–74
   PubMed Web of Science ®Google Scholar
• Hsieh R-K, Chang A Y-C, Boros L, Asbury R. Phase II study of ifosfam-ide, carboplatin, and etoposide in patients with advanced non-small cell lung cancer. Am J Clin Oncol 1994; 17: 509–513
   PubMed Web of Science ®Google Scholar
• Loehrer PJ, Lauer R, Roth BJ. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Ann Intern Med 1988; 87: 540–547
   Google Scholar
• Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investiga-tional antimicrotubule agent. J Natl Cancer Inst 1990; 82: 1247–1259
   PubMed Web of Science ®Google Scholar
• Smith IE, Perren TJ, Ashley SA, et al. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. J Clin Oncol 1990; 8: 899–905
   PubMed Web of Science ®Google Scholar
• Van Zandwijk N, ten Bokkel Huinink WW, Wanders J, et al. Dose finding studies with carboplatin, ifosfamide, etoposide and mesna in non-small cell lung cancer. Semin Oncol 1990; 17(suppl 2)16–19
   PubMedGoogle Scholar
• Czuczman M, Grillo-Lopez AJ, Saleh M, et al. Phase II clinical trial of IDEC-C2B8/CHOP combination therapy in low-grade lymphoma: preliminary results. Proc ASCO 1995; 14: 401, (#1261)
   Google Scholar
• Demidem A, Hanna N, Hariharan H, et al. Chimeric anti-CD20 antibody (IDEC-C2B8) is apoptotic and sensitizes drug resistant human B-cell lymphomas and AIDS related lymphomas to the cytotoxic effect of CDDP, VP-16, and toxins. FASEB 1995; 9: A206
   Web of Science ®Google Scholar
• Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by per before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991; 325: 1525–1533
   PubMed Web of Science ®Google Scholar
• Gribben JG, Freedman AS, Woo SD, et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction ampliflable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 12: 3275–3280
   Google Scholar
• Gribben JG, Neuberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449–3457
   PubMed Web of Science ®Google Scholar
• Hsu B, Marin M, Brisbay S, et al. Expression of bcl-2 gene confers multi-drug resistance to chemotherapy-induced cell death. Cancer Bull 1994; 46: 125–129
   Google Scholar
• Johnson P WM, Price C GA, Smith T, et al. Detection of cells bearing the t(14;18) translocation following myeloablative treatment and autologous bone marrow transplantation for follicular lymphoma. J Clin Oncol 1994; 12: 798–805
   PubMed Web of Science ®Google Scholar
• Maloney DG, Bodkin D, Grillo-Lopez AJ, et al. IDEC-C2B8: final report on a phase II trial in relapsed non-Hodgkin's lymphoma. Blood 1994; 84: 169a, (#661)
   PubMed Web of Science ®Google Scholar
• Maloney DG, Liles TM, Gzerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994; 84: 2457–2466
   PubMed Web of Science ®Google Scholar
• Hughes K, Steele J, Sugarbaker P. Surgery for colorectal cancer metastatic to the liver. Surg Clin N Am 1989; 69: 339–359
   PubMed Web of Science ®Google Scholar
• Registry of Hepatic Metastases. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of indications for resection. Surgery 1988; 103: 278–288
   PubMed Web of Science ®Google Scholar
• Hughes KS, Rosenstein R, Songohoradbodi S, et al. Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of long-term survivors. Dis Colon Rectum 1988; 31: 1–4
   PubMed Web of Science ®Google Scholar
• Fong Y, Blumgart L, Cohen A. Surgical treatment of colorectal metastases to the liver. CA—Cancer J Clin 1995; 45: 50–62
   PubMed Web of Science ®Google Scholar
• Fisher B, Wolmark N, Bauer M, Redmond C, Gebhardt M. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 1981; 152: 765–772
   PubMedGoogle Scholar
• Boring CC, Squires TS, Tong T, Montgomery S. Cancer statistics, 1994. CA—Cancer J Clin 1994; 44: 7–26
   PubMed Web of Science ®Google Scholar
• Harris JR, Morrow M, Bonadonna G. Cancer of the breast. Cancer. Principles and Practice of Oncology, 4th ed, VT DeVita, Jr, S Hellman, SA Rosenberg. JB Lippincott, Philadelphia 1993; vol. 1: 1264–1315
   Google Scholar
• Goldenberg DM. New developments in monoclonal antibodies for cancer detection and therapy. CA—Cancer J Clin 1994; 44: 43–64
   PubMed Web of Science ®Google Scholar
• Lamki LM, Buzdar AU, Singletary SE, Rosenblum MG, Bhadkamkar V, Esparza L, Podoloff D, Zukiwski A, Hortobagyi GN, Murray JL. Indium-111-labeled B72.3 monoclonal antibody in the detection and staging of breast cancer: a phase I study. J Nucl Med 1991; 32: 1326–1332
   PubMed Web of Science ®Google Scholar
• Lind P, Smola MG, Lechnner P, Ratschek M, Klima G, Koltringer P, Stendorfer P, Eber O. The immunoscintigraphic use of Tc99m-labeled monoclonal anti-CEA antibodies (BW 431/26) in patients with suspected primary, recurrent and metastatic breast cancer. Int J Cancer 1991; 47: 865–869
   PubMed Web of Science ®Google Scholar
• De Jager R, Abdel-Nabi H, Serafini A, Pecking A, Klein JL, Hanna MG, Jr. Current status of immunodetection with radiolabeled human monoclonal antibodies. Semin Nucl Med 1993; 23: 165–179
   PubMed Web of Science ®Google Scholar
• Fisher GA, Sikic BI. Clinical studies with modulators of multidrug resistance. Drug Resistance in Clinical Oncology and Hematology, GA Fisher, BI Sikic. WB Saunders, Philadelphia 1995; Vol. 9: 363–382, Hematology/Oncology Clinics of North America, No. 2
   Google Scholar
• Sikic BI. Modulation of multidrug resistance; at the threshold (editorial). J Clin Oncol 1993; 11: 1629–1635
   PubMed Web of Science ®Google Scholar
• Yuen AR, Sikic BI. Multidrug resistance in lymphomas. J Clin Oncol 1994; 12: 2453–2459
   PubMed Web of Science ®Google Scholar
• Biesecker B, Boehnke M, Calzone K, et al. Genetic counseling for families with inherited susceptibility to breast and ovarian cancer. J Am MedAssoc 1993; 269(15)1970–1974
   Web of Science ®Google Scholar
• Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford J, Lindblom A, Tannergard P, Bollag RJ, Godwin AR, Ward DC, Nordenskjold M, Fishel R, Kolodner R, Liskay RM. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary nonpolyposis colon cancer. Nature 1994; 368: 258–261
   PubMed Web of Science ®Google Scholar
• Claus EB, Risch N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Human Genet 1991; 48: 232–242
   PubMed Web of Science ®Google Scholar
• Claus EB, Risch N, Thompson WD. Autosomal dominant inheritance of early-onset breast cancer. Cancer 1994; 73: 643–651
   PubMed Web of Science ®Google Scholar
• Easton D, Bishop D, Ford D, et al. Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. Am J Hum Genet 1993; 52: 678–701
   PubMed Web of Science ®Google Scholar
• Easton DF, Ford D, Bishop DT, the Breast Cancer Linkage Consortium. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Am J Hum Genet 1995; 55: 265–271
   Google Scholar
• Fishel R, Lescoe MK, Rao M RS, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1993; 75: 1027–1038
   PubMed Web of Science ®Google Scholar
• Ford D, Easton DF, Bishop DT. Risks of cancer in BRCA1 mutation carriers. Lancet 1994; 343: 692–695
   PubMed Web of Science ®Google Scholar
• Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 1994; 266: 120–122
   PubMed Web of Science ®Google Scholar
• Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q. Science 1990; 250: 1684–1689
   PubMed Web of Science ®Google Scholar
• Hoskins KF, Stopfer JE, Calzone KA, Merajver SD, Rebbeck TR, Garber JE, Weber BL. Assessment and counseling for women with a family history of breast cancer. J Am Med Assoc 1995; 273(7)577–585
   PubMed Web of Science ®Google Scholar
• Lerman C, Croyle R. Psychological issues in genetic testing for breast cancer susceptibility. Arch Intern Med 1994; 154: 609–615
   PubMed Web of Science ®Google Scholar
• Li FP, Fraumeni JF, Mulvihill JJ, et al. A cancer family syndrome in 24 kindreds. Cancer Res 1988; 48: 5358–5362
   PubMed Web of Science ®Google Scholar
• Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990; 250: 1233–1238
   PubMed Web of Science ®Google Scholar
• Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71
   PubMed Web of Science ®Google Scholar
• Narod SA, Feunteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on chromosome 17ql2-q23. Lancet 1991; 338: 82–83
   PubMed Web of Science ®Google Scholar
• Shattuck-Eidens D, McClure M, Simard J, et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene: implications for presymptomatic testing and screening. J Am Med Assoc 1995; 273: 535–541
   PubMed Web of Science ®Google Scholar
• Stratum M, Ford D, Neuhasen S, et al. Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q. Nature Genetics 1994; 7: 103–107
   PubMed Web of Science ®Google Scholar
• Wooster R, Neuhausen S, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13ql2–13. Science, 265: 2088–2089
   PubMed Web of Science ®Google Scholar
• Dillman RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994; 12: 1497–1515
   PubMed Web of Science ®Google Scholar
• Fanger MW, Morganelli PM, Guyre PM. Use of bispecific antibodies in the therapy of tumors. Cancer Treat Res 1993; 68: 181–194
   PubMedGoogle Scholar
• Fanger MW, Segal DM, Romet-Lemonne JL. Bispecific antibodies and targeted cellular cytotoxicity. ImmunolToday 1991; 12: 51–55
   Web of Science ®Google Scholar
• Schlom J. Basic principles and applications of monoclonal antibodies in the management of carcinomas. Cancer Res. 1986; 46: 3225–3238
   PubMed Web of Science ®Google Scholar
• Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 (anti-HER-2/neu × anti-FcγRI) in patients with advanced breast or ovarian cancer that overexpress the protooncogene HER-2/neu. J Clin Oncol, In press
   Web of Science ®Google Scholar
• Weiner LM, Holmes M, Adams GP, et al. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 1993; 53: 94–100
   PubMed Web of Science ®Google Scholar
• Frei E, III. Combination cancer chemotherapy: presidential address. Cancer Res 1972; 32: 2593–2607
   PubMed Web of Science ®Google Scholar
• Frei E, III, Canellos GP. Dose, a critical factor in cancer chemotherapy. Am J Med 1980; 69: 585–594
   PubMed Web of Science ®Google Scholar
• Frei E, III, Antman KH. Combination chemotherapy, dose, and schedule: section XV: principles of Chemotherapy. Cancer Medicine, JF Holland, E Frei, III, RC Bast, Jr, DW Kufe, DI Morton, RR Weichselbaum. Lea and Febiger, Philadelphia 1993; 631–639
   Google Scholar
• Seiner EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol 1988; 15(3)278–299
   PubMed Web of Science ®Google Scholar
• Osterlind K, Hansen HH, Hansen M, Dombernowsky P, Andersen PK. Long-term disease-free survival in small-cell carcinoma of the lung: a study of clinical determinants. J Clin Oncol 1986; 4(9)1307–1313
   PubMed Web of Science ®Google Scholar
• Pignon JP, Arriagada R, Ihde DC, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med 1992; 327: 1618–1624
   PubMed Web of Science ®Google Scholar
• Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? a meta-analysis. J Clin Oncol 1992; 10: 890–895
   PubMed Web of Science ®Google Scholar
• Teicher BA. Preclinical models for high-dose therapy. High-dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, JO Armitage, KH Antman. Williams and Wilkins, Baltimore 1992; 14–42
   Google Scholar
• Cohen MH, Creaven PJ, Fossieck BE, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep 1977; 61: 349–354
   PubMedGoogle Scholar
• Brower M, Ihde DC, Johnson-Early A, et al. Treatment of extensive stage small cell bronchogenic carcinoma: effects of variation in intensity of induction chemotherapy. Am J Med 1983; 75: 993–1000
   PubMed Web of Science ®Google Scholar
• Johnson DH, Einhorn LH, Birch R, et al. A randomized comparison of high dose versus conventional dose cyclophosphamide, doxorubicin, and vincristine for extensive stage small cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 1987; 5: 1731–1738
   PubMed Web of Science ®Google Scholar
• Mehta C, Vogl SE. High-dose cyclophosphamide in the induction therapy of small cell lung cancer: minor improvements in rate of remission and survival. Proc AACR 1982; 23: 155
   Google Scholar
• Figueredo AT, Hryniuk WM, Strautmanis I, et al. Co-trimoxazole prophylaxis during high-dose chemotherapy of small-cell lung cancer. J Clin Oncol 1985; 3: 54–64
   PubMed Web of Science ®Google Scholar
• Ihde DC, Mulshine JL, Kramer BS, Steinberg SM, Linnoila RI, Gazdar AF, Edison M, Phelps RM, Lesar M, Phares JC, Grayson J, Minna JD, Johnson BE. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 1994; 12: 2022–2034
   PubMed Web of Science ®Google Scholar
• Arriagada R, Le Chevalier T, Pignon J-P, Riviere A, Monnet I, Chomy P, Tuchais C, Tarayre M, Ruffle P. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med 1993; 329: 1848–1852
   PubMed Web of Science ®Google Scholar
• Elias AD, Cohen BF. Dose-intensive therapy in lung cancer. High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells, 2nd ed., JO Armitage, KH Antman. Williams and Wilkins, Baltimore 1995; 824–846
   Google Scholar
• Humblet Y, Symann M, Bosly A, et al. Late intensification chemotherapy with autologous bone marrow transplantation in selected small-cell carcinoma of the lung: a randomized study. J Clin Oncol 1987; 5: 1864–1873
   PubMed Web of Science ®Google Scholar
• Elias AD, Ayash L, Frei E, III, Skarin AT, Hunt M, Wheeler C, Schwartz G, Mazanet R, Tepler I, Eder JP, McCauley M, Herman T, Schnipper L, Antman KH. Intensive combined modality therapy for limited stage small cell lung cancer. J Nad Cancer Inst 1993; 85: 559–566
   PubMed Web of Science ®Google Scholar
• McCracken JD, Janaki LM, Crowley JJ, Taylor SA, Giri P GS, Weiss GB, Gordon W, Baker LH, Mansouri A, Kuebler JP. Concurrent chemotherapy/radiotherapy for limited small-cell lung carcinoma: a Southwest Oncology Group Study. J Clin Oncol 1990; 8: 892–898
   PubMed Web of Science ®Google Scholar
• Turrisi AT, Glover DJ, Mason BA. A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. Int J Radial Oncol Biol Phys 1988; 15: 183–187
   Web of Science ®Google Scholar
• Turrisi A, Wagner H, Glover D, Mason B, Oken M, Bonomi P. Limited small cell lung cancer: concurrent BID thoracic radiotherapy with platinum-etoposide: an ECOG Study. Proc ASCO 1990; 9: 230, C-887
   Google Scholar
• Johnson DH, Turrisi AT, Chang AY, Wagner H, Blum R. Alternating chemotherapy and thoracic radiotherapy in limited small cell lung cancer: a test of the Looney hypothesis. Proc ASCO 1991; 10: 243, C-829
   Google Scholar
• Turrisi AT, Kim K, Johnson DH, Komaki R, Sause W, Curran W, Livingston R, Wagner H, Blum R. Daily (qd) v twice-daily (bid) thoracic irradiation (TI) with concurrent cisplatin-etoposide (PE) for limited small cell lung cancer (LSCLC): preliminary results on 352 randomized eligible patients. Lung Cancer 1994; 11(suppl 1)172, 667
   Google Scholar
• Choi NC. Verbal communication. CALGB Fall Meeting, Atlanta, GA, November, 1994
   Google Scholar
• Brugger W, Brass KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636–640
   PubMed Web of Science ®Google Scholar
• Ross AA, Cooper BW, Lazarus HM, Mackay W, Moss TJ, Ciobanu N, Tallman MS, Kennedy MJ, Davidson NE, Sweet D, Winter C, Akard L, Jansen J, Copelan E, Meagher RC, Herzig RH, Klumpp TR, Kahn DG, Warner NE. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993; 82: 2605–2610
   PubMed Web of Science ®Google Scholar
• Greenspan EM, Feiber M, Lesnick G, et al. Response of advanced breast carcinoma to the combination of the antimetabolite methotrexate and the alkylating agent thiotepa. J Mt Sinai Hosp 1963; 30: 246–267
   PubMedGoogle Scholar
• Cooper RG. Combination chemotherapy in hormone resistant breast cancer. Proc Am Assoc Cancer Res 1969; 10: 15
   Web of Science ®Google Scholar
• Smith IE, Walsh G, Jones A, Prendiville J, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995; 13: 424–429
   PubMed Web of Science ®Google Scholar
• Henderson IC. (Letter). N Engl J Med 1992; 327(18)1218
   Google Scholar
• Henderson IC. Breast cancer therapy—the price of success. N Engl J Med 1992; 326(26)1774–1775
   PubMed Web of Science ®Google Scholar
• Osborne CK. Prognostic factors for breast cancer: Have they met their promise. J Clin Oncol 1992; 10(5)679–682
   PubMed Web of Science ®Google Scholar
• Greenspan EM, Erlich R. Inflammatory breast cancer. Preneoplastic and Early Breast Cancer. Williams and Wilkins, Baltimore 1993; 280–292
   Google Scholar
• Greenspan EM. Combination cytotoxic chemotherapy in advanced disseminated breast carcinoma. J Mt Sinai Hosp 1966; 33: 1–27
   PubMedGoogle Scholar
• Greenspan EM. Introduction and Breast Cancer chapters. Clinical Interpretation and Practice of Cancer Chemotherapy. Raven Press, New York 1982; 1–15; 145–194
   Google Scholar
• Hortobagyi GN, Buzdar AU. Ten year survival after chemotherapy for high risk primary and metastatic breast carcinoma. Cancer Invest 1992; 10(1)12, abstract 11
   Google Scholar
• Krown S AE, Pinsky CM, Wanebo HJ, et al. Immunologic reactivity and prognosis in breast cancer. Cancer 1980; 46: 1746–1752
   PubMed Web of Science ®Google Scholar
• Fisher B, Redmond CK, Fisher ER, et al. Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project experience. NCI Monographs. Ntl Cancer Inst 1986; 1: 35–43
   Google Scholar
• Nissen-Mayer R, Host H, Kjellgren K, et al. Short perioperative versus long-term adjuvant chemotherapy: perioperative chemotherapy: rationale, risk and results. Recent Results in Cancer Research. Springer-Verlag, Berlin 1985; 91–98
   Google Scholar
• Holland J, Glidewell O, Cooper RG. Adverse effect of radiotherapy on adjuvant chemotherapy for cancer of the breast. Surg Gyn Obstet 1980; 150(6)817–821
   PubMedGoogle Scholar
• Perloff M, Norton L, Korzun A, et al. Advantage of an adriamycin combination plus halotestine after initial cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisone for adjuvant therapy of node-positive stage II breast cancer. Proc ASCO 1986; 5(273)780
   Google Scholar
• McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary-node negative breast cancer. N Engl J Med 1992; 326(26)1756–1761
   PubMed Web of Science ®Google Scholar
• McKay MJ, Langlands AO. (Letter). N Engl J Med 1992; 327(18j)1817
   PubMedGoogle Scholar
• Clark GM, Osbome CK. (Letter). N Engl JMed 1992; 327(18)1318
   Google Scholar
• Evans RA. (Letter). N Engl J Med 1992; 3278(18)13217–1318
   Google Scholar
• Greenspan EM. Breast cancer (letter). The Lancet 1994; 344: 8934
   Google Scholar
• Haybittle JL. Is breast cancer ever cured. Rev Endocrine Related Cancer 1983; 14: 13–18
   Google Scholar
• Adjuvant systemic therapy for early breast cancer. The Lancet 1992; 339(8784)27–28, Editorial
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. The Lancet 1992; 339(8784)1–14
   PubMed Web of Science ®Google Scholar
• Adler A, Stein JA, Ben-Efraim S. Immunocompetence, immunosuppression and human breast cancer. Cancer 1980; 45: 2061–2083
   PubMed Web of Science ®Google Scholar
• Mandeville A, Lamoureux G, Legault-Poisson S, et al. Biological markers and breast cancer: multiparametric study II: depressed immunocompetence. Cancer 1982; 50: 1280–1288
   PubMed Web of Science ®Google Scholar
• Greenspan EM. Is there a relation between previous tuberculosis and long-term survival after solid tumor chemotherapy. Cancer Treat Rep 1982; 667: 206–208
   Google Scholar
• Greenspan EM. Prior tuberculosis in long-term survivors of breast and ovarian cancer from a New York oncology practice (1954–1974). Mt Sinai J Med 1985; 52: 465–468
   PubMed Web of Science ®Google Scholar
• Greenspan EM. Is BCG an “orphan” drug suffering from chemo-therapists' overkill. Cancer Invest 1986; 4(1)81–92
   PubMed Web of Science ®Google Scholar
• Cody H S HI, Urban JA. Is the major prognosticator in axillary node-negative breast cancer being overlooked? The importance of internal mammary node status in 195 extended radical mastectomy patients followed ten years. Ann Surg Oncol 1994, in press
   Google Scholar
• Greenspan EM. The Breast Cancer Epidemic in the United States, 4th ed. Chemotherapy Foundation, New York 1994, How 15,000 More Lives Can Be Saved Each Year
   Google Scholar